Dual leucine zipper kinase as a therapeutic target for neurodegenerative conditions.

Dana Ferraris, Zhiyong Yang, Derek Welsbie

Research output: Contribution to journalReview articlepeer-review


Dual leucine zipper kinase (DLK) is a serine/threonine protein kinase that is a member of the mixed lineage kinase subfamily. Mixed lineage kinases are upstream MAP3Ks that activate the JNK pathway. DLK is primarily responsible for activating JNK and mediating the apoptotic stress response in various cell types, specifically neurons. Inhibition and knockdown of DLK has been demonstrated to have neuroprotective effects in cellular and animal models of Alzheimer's disease, glaucoma, Parkinson's disease and other neurodegenerative conditions. Several series of ATP-binding site inhibitors have been identified through profiling efforts providing launch points for future medicinal chemistry programs.

Original languageEnglish (US)
Pages (from-to)1923-1934
Number of pages12
JournalFuture medicinal chemistry
Issue number16
StatePublished - Oct 2013
Externally publishedYes

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Dual leucine zipper kinase as a therapeutic target for neurodegenerative conditions.'. Together they form a unique fingerprint.

Cite this